Aer Therapeutics has raised a $36M Series A funding round to develop therapies for lung diseases.
The company is a spin-out of University College Dublin and the University of California, San Francisco.
- Aer Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing therapies for conditions such as asthma, bronchiectasis, cystic fibrosis, etc.
- Aer's solution targets excess mucus and mucus plugs created from respiratory complications.
- This round was led by Canaan, OrbiMed, and Hatteras Venture Partners.
- The company is based in Raleigh, North Carolina.
